MX357708B - Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro. - Google Patents

Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.

Info

Publication number
MX357708B
MX357708B MX2014007177A MX2014007177A MX357708B MX 357708 B MX357708 B MX 357708B MX 2014007177 A MX2014007177 A MX 2014007177A MX 2014007177 A MX2014007177 A MX 2014007177A MX 357708 B MX357708 B MX 357708B
Authority
MX
Mexico
Prior art keywords
iron
related disorders
diagnosis
treatment
composition
Prior art date
Application number
MX2014007177A
Other languages
English (en)
Other versions
MX2014007177A (es
Inventor
Mueller Bernhard
Popp Andreas
M Perez Jennifer
Original Assignee
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Deutschland filed Critical Abbvie Deutschland
Publication of MX2014007177A publication Critical patent/MX2014007177A/es
Publication of MX357708B publication Critical patent/MX357708B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a métodos para utilizar los anticuerpos que se unen a RGMc para tratar y diagnosticar trastornos relacionados con hierro.
MX2014007177A 2011-12-14 2012-12-13 Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro. MX357708B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161570715P 2011-12-14 2011-12-14
PCT/US2012/069586 WO2013090635A2 (en) 2011-12-14 2012-12-13 Composition and method for the diagnosis and treatment of iron-related disorders

Publications (2)

Publication Number Publication Date
MX2014007177A MX2014007177A (es) 2014-10-17
MX357708B true MX357708B (es) 2018-07-20

Family

ID=47436267

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014007177A MX357708B (es) 2011-12-14 2012-12-13 Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
MX2018008882A MX2018008882A (es) 2011-12-14 2014-06-13 Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018008882A MX2018008882A (es) 2011-12-14 2014-06-13 Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.

Country Status (8)

Country Link
US (4) US10118958B2 (es)
EP (2) EP2791173B1 (es)
JP (5) JP6342812B2 (es)
CN (2) CN104144947B (es)
AU (4) AU2012352168C1 (es)
CA (2) CA3204283A1 (es)
MX (2) MX357708B (es)
WO (1) WO2013090635A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6342812B2 (ja) * 2011-12-14 2018-06-13 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 鉄関連障害を診断および治療するための組成物および方法
US20150164991A1 (en) * 2013-11-01 2015-06-18 Vanderbilt University Method and Kit for Evaluating and Monitoring a Treatment Program for Anemia
JP6663428B2 (ja) 2014-10-30 2020-03-11 アクセルロン ファーマ， インコーポレイテッド Ｇｄｆ１５ポリペプチドを使用する、赤血球を増加させるための方法および組成物
IL287291B (en) * 2015-04-28 2022-09-01 Univ Osaka A protein that binds to rgma and its use
EP3870286A1 (en) * 2018-10-23 2021-09-01 Scholar Rock, Inc. Rgmc-selective inhibitors and use thereof
WO2021062171A1 (en) * 2019-09-27 2021-04-01 Disc Medicine, Inc. Methods for treating anemia of chronic disease
WO2021062163A1 (en) * 2019-09-27 2021-04-01 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
JP2021167795A (ja) 2020-04-13 2021-10-21 国立大学法人大阪大学 血液分析装置
MX2022014254A (es) * 2020-05-13 2023-02-16 Disc Medicine Inc Anticuerpos anti-hemojuvelina (hjv) para tratar mielofibrosis.
CA3177888A1 (en) * 2020-05-13 2021-11-18 Maria BECONI Anti-hemojuvelin (hjv) antibodies for treating anemia of chronic disease
EP4433160A1 (en) * 2021-11-17 2024-09-25 Disc Medicine, Inc. Methods for treating anemia of kidney disease

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US938A (en) 1838-09-22 Improvement in paddle-wheels for propelling boats
US4526A (en) 1846-05-16 Improvement in the mode o
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
CH0229046H1 (de) 1985-03-30 1998-07-15 Stuart Alan Kauffman Method for obtaining dna, rna, peptides, polypeptinique. des or proteins by means of a dna recombinant tech
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5635600A (en) 1986-07-07 1997-06-03 Trustees Of Dartmouth College Bifunctional and heteroantibodies specific for the high affinity Fc receptor for immunoglobulin G on human mononuclear phagocytes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0273115B1 (en) 1986-10-22 1994-09-07 Abbott Laboratories Chemiluminescent acridinium and phenanthridinium salts
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5241070A (en) 1988-09-26 1993-08-31 Ciba Corning Diagnostics Corp. Nucleophilic polysubstituted aryl acridinium esters and uses thereof
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
EP0550436A1 (en) 1989-11-06 1993-07-14 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
US5135875A (en) 1990-08-15 1992-08-04 Abbott Laboratories Protein precipitation reagent
CA2048302A1 (en) 1990-08-15 1992-02-16 Victoria P. Meucci Solubilization reagent for biological test samples
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
DK1279731T3 (da) 1991-03-01 2007-09-24 Dyax Corp Fremgangsmåde til udvikling af bindende miniproteiner
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
EP0585310B1 (en) 1991-04-10 1999-03-17 Biosite Diagnostics Inc. Crosstalk inhibitors and their uses
ES2150915T3 (es) 1991-04-12 2000-12-16 Biosite Diagnostics Inc Nuevos conjugados y dosificados destinados para la deteccion simultanea de ligandos multiples.
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法
CA2069530A1 (en) 1991-06-03 1992-12-04 Cass J. Grandone Reagent pack for immunoassays
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
ES2313867T3 (es) 1991-12-02 2009-03-16 Medical Research Council Produccion de anticuerpos anti-auto de repertorios de segmentos de anticuerpo expresados en la superficie de fagos.
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5352803A (en) 1992-03-30 1994-10-04 Abbott Laboratories 5(6)-methyl substituted fluorescein derivatives
WO1993020442A1 (en) 1992-03-30 1993-10-14 Abbott Laboratories Reagents and methods for the detection and quantification of thyroxine in fluid samples
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
EP1231268B1 (en) 1994-01-31 2005-07-27 Trustees Of Boston University Polyclonal antibody libraries
EP0749325B1 (en) 1994-03-07 2002-06-12 Medarex, Inc. Bispecific molecules having clinical utilities
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6111166A (en) 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
EP0805678B1 (en) 1995-01-05 2003-10-29 THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN Surface-modified nanoparticles and method of making and using same
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
WO1996033266A1 (en) 1995-04-21 1996-10-24 Cell Genesys, Inc. Generation of large genomic dna deletions
EP1709970A1 (en) 1995-04-27 2006-10-11 Abgenix, Inc. Human antibodies against EGFR, derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
CA2230494A1 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
NZ512006A (en) 1996-02-09 2005-05-27 Abbott Biotech Ltd Medical treatment with human TNF-alpha antibodies
DK0885002T3 (da) 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6017517A (en) 1996-12-18 2000-01-25 The Dial Corporation Method for treating human nails
WO1998031346A1 (en) 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO1998031700A1 (en) 1997-01-21 1998-07-23 The General Hospital Corporation Selection of proteins using rna-protein fusions
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
WO1999028349A2 (en) 1997-12-02 1999-06-10 Medarex, Inc. CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS
CA2322749A1 (en) 1998-03-03 1999-09-10 Abgenix, Inc. Cd147 binding molecules as therapeutics
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
JP2002518432A (ja) 1998-06-24 2002-06-25 アドバンスト インハレーション リサーチ，インコーポレイテッド 吸入器から放出される大多孔性粒子
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
JP3793693B2 (ja) 1998-12-23 2006-07-05 ファイザー インコーポレーテッド Ｃｔｌａ−４に対するヒトモノクローナル抗体
US6231768B1 (en) 1999-01-19 2001-05-15 Nalco Chemical Company Rheology modification of settled solids in mineral processing
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
CN101066997B (zh) * 1999-03-25 2013-03-27 艾博特股份有限两合公司 结合人il-12的人抗体及其生产方法
US6984720B1 (en) 1999-08-24 2006-01-10 Medarex, Inc. Human CTLA-4 antibodies
EP1257585A2 (en) 2000-02-10 2002-11-20 Basf Aktiengesellschaft Antibodies that bind human interleukin-18 and methods of making and using
MXPA02012867A (es) 2000-06-29 2003-09-05 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos.
US6925389B2 (en) 2000-07-18 2005-08-02 Correlogic Systems, Inc., Process for discriminating between biological states based on hidden patterns from biological data
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US6890763B2 (en) 2001-04-30 2005-05-10 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1350 daltons
ATE434040T1 (de) 2001-10-01 2009-07-15 Dyax Corp Mehrkettige eukaryontische display-vektoren und deren verwendungen
US7419821B2 (en) 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
US6989100B2 (en) 2002-05-09 2006-01-24 Ppd Biomarker Discovery Sciences, Llc Methods for time-alignment of liquid chromatography-mass spectrometry data
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
CN1942588B (zh) 2003-03-05 2013-06-12 海洋酶公司 可溶性透明质酸酶糖蛋白(sHASEGP)、制备它们的方法、它们的用途和包含它们的药物组合物
JP2007528723A (ja) 2003-08-22 2007-10-18 メディミューン，インコーポレーテッド 抗体のヒト化
US7682833B2 (en) 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
ES2547866T3 (es) 2005-02-16 2015-10-09 The General Hospital Corporation Uso de proteínas de fusión de hemojuvelina para regular el metabolismo del hierro mediado por hepcidina
US7534764B2 (en) 2005-06-29 2009-05-19 The Regents Of The University Of California Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin
EP2495257A3 (en) 2005-08-19 2012-10-17 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
US7906293B2 (en) 2007-04-09 2011-03-15 Abbott Laboratories Acridinium phenyl esters useful in the analysis of biological
EP2033971A1 (de) 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
ES2527072T3 (es) 2008-03-19 2015-01-19 China Synthetic Rubber Corporation Procedimientos y agentes para el diagnóstico y el tratamiento de carcinoma hepatocelular
EP2349332B1 (en) 2008-11-13 2019-10-23 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation bmp-6
US20110293526A1 (en) 2008-11-20 2011-12-01 University Of Southern California Compositions and methods to modulate hair growth
WO2010078443A1 (en) 2008-12-31 2010-07-08 Abbott Point Of Care Inc. Method and device for immunoassay using nucleotide conjugates
ES2562832T3 (es) * 2009-12-08 2016-03-08 Abbvie Deutschland Gmbh & Co Kg Anticuerpos monoclonales contra la proteína RGM para su uso en el tratamiento de la degeneración de la capa de fibra nerviosa de la retina
CN107022032A (zh) 2011-01-19 2017-08-08 菲卢马克斯制药公司 用于调节铁稳态的组合物及其使用方法
JP6342812B2 (ja) * 2011-12-14 2018-06-13 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 鉄関連障害を診断および治療するための組成物および方法
WO2021062171A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. Methods for treating anemia of chronic disease
WO2021062163A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
CA3177888A1 (en) 2020-05-13 2021-11-18 Maria BECONI Anti-hemojuvelin (hjv) antibodies for treating anemia of chronic disease
MX2022014254A (es) 2020-05-13 2023-02-16 Disc Medicine Inc Anticuerpos anti-hemojuvelina (hjv) para tratar mielofibrosis.
EP4433160A1 (en) 2021-11-17 2024-09-25 Disc Medicine, Inc. Methods for treating anemia of kidney disease

Also Published As

Publication number Publication date
US20190292244A1 (en) 2019-09-26
JP6926176B2 (ja) 2021-08-25
JP2015502753A (ja) 2015-01-29
US20210155681A1 (en) 2021-05-27
CA2855840A1 (en) 2013-06-20
AU2012352168C1 (en) 2018-01-25
WO2013090635A3 (en) 2013-09-26
CN107459576A (zh) 2017-12-12
JP2021191267A (ja) 2021-12-16
MX2014007177A (es) 2014-10-17
AU2017235976B2 (en) 2019-08-22
WO2013090635A2 (en) 2013-06-20
AU2022200452A1 (en) 2022-02-17
CA3204283A1 (en) 2013-06-20
AU2012352168A1 (en) 2014-05-01
JP7238042B2 (ja) 2023-03-13
AU2019261820B2 (en) 2021-10-28
CN104144947A (zh) 2014-11-12
AU2012352168B2 (en) 2017-06-29
EP2791173B1 (en) 2020-07-29
CA2855840C (en) 2023-08-29
US20130330343A1 (en) 2013-12-12
JP2018148908A (ja) 2018-09-27
CN104144947B (zh) 2017-10-27
US12098192B2 (en) 2024-09-24
EP2791173A2 (en) 2014-10-22
AU2017235976A1 (en) 2017-10-19
JP2020058359A (ja) 2020-04-16
JP6342812B2 (ja) 2018-06-13
JP2023078174A (ja) 2023-06-06
US12098189B2 (en) 2024-09-24
MX2018008882A (es) 2021-06-15
BR112014013656A2 (pt) 2020-10-27
EP3800200A1 (en) 2021-04-07
US10118958B2 (en) 2018-11-06
US10822403B2 (en) 2020-11-03
US20240262901A1 (en) 2024-08-08
AU2019261820A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
MX2018008882A (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
CY1122278T1 (el) Αντι il-36r αντισωματα
MX2022004300A (es) Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas.
PH12017500864A1 (en) Anti-notch1 antibodies
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
MX2017008819A (es) Anticuerpos anti-cd47 y usos de los mismos.
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
MX356933B (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
PH12014502406A1 (en) Anti-il-23p19 antibodies
MX2019000046A (es) Anticuerpos anti-il-23.
WO2013056148A3 (en) Scd1 antagonists for treating cancer
EA201391332A1 (ru) Лиганды опиоидных рецепторов и способы их применения и получения
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
MX2013001267A (es) ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
EA201491286A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
GB201109238D0 (en) Antibodies
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
PH12015501360A1 (en) Bmp-6 antibodies
SG194235A1 (en) Methods of predicting the development of complement-mediated disease
WO2012166659A3 (en) Anti-emr1 antibodies
TN2014000207A1 (en) Anti il-36r antibodies
TN2013000186A1 (en) Anti-il-23 antibodies
TN2013000265A1 (en) Anti-cd38 antibodies

Legal Events

Date Code Title Description
FG Grant or registration